Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran versus enoxaparin for coagulation activation in Staphylococcus aureus bacteremia
2009-009056-20Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of dabigatran in Staphylococcal bacteremia and Staphylococcus epidermidis bacteremia (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Reduction in D-dimer from day 1 to day 4. Started Feb 2009; status: completed.
02
Drugs
dabigatran
03
Conditions
Staphylococcal bacteremiaStaphylococcus epidermidis bacteremia
Beyond the preview
Go deeper on 2009-009056-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009056-20.